This study aimed to evaluate the prevalence and spectrum of 13 BRCA1 and BRCA2 founder mutations most frequently observed in the area of Central Europe in unselected patients from Belarus diagnosed with ovarian cancer. This evidence concerns the gene BRCA1 and ovarian carcinoma.